MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study
Open Access
- 21 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Evidence accumulated so far indicates that circulating levels of microRNAs (miRNAs) are associated with several pathologies. Therefore, differential expression of extracellular miRNAs exhibits promising potential for screening and diagnosis purposes. We evaluated plasma miRNAs in response to the lipid-lowering drug atorvastatin in patients with hypercholesterolemia (HC) and controls. Methods: We selected miRNAs based on previous data reported by our group and also by employing bioinformatics tools to identify 10 miRNAs related to cholesterol metabolism and statin response genes. Following miRNA identification, we determined plasma levels of miRNA-17-5p, miRNA-30c-5p, miRNA-24-3p, miRNA-33a-5p, miRNA-33b-5p, miRNA-29a-3p, miRNA-29b-3p, miRNA-454-3p, miRNA-590-3p and miRNA-27a-3p in 20 HC patients before and after 1 month of 20 mg/day atorvastatin treatment, evaluating the same miRNA set in a group of 20 healthy subjects, and employing qRT-PCR to determine differential miRNAs expression. Results: HC individuals showed significant overexpression of miRNA-30c-5p and miRNA-29b-3p vs. NL (p = 0.0008 and p = 0.0001, respectively). Once cholesterol-lowering treatment was concluded, HC individuals showed a substantial increase of three extracellular miRNAs (miRNA-24-3p, miRNA-590, and miRNA-33b-5p), the latter elevated more than 37-fold (p = 0.0082). Conclusion: Data suggest that circulating miRNA-30c-5p and miRNA-29b-3p are associated with hypercholesterolemia. Also, atorvastatin induces a strong elevation of miRNA-33b-5p levels in HC individuals, which could indicate an important function that this miRNA may exert upon atorvastatin therapy. Additional studies are needed to clarify the role of this particular miRNA in statin treatment.Keywords
Funding Information
- Fondo Nacional de Desarrollo Científico y Tecnológico
- Universidad de La Frontera
This publication has 26 references indexed in Scilit:
- miRTarBase 2020: updates to the experimentally validated microRNA–target interaction databaseNucleic Acids Research, 2019
- Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular diseaseHeart, 2019
- Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort StudyClinical Pharmacology & Therapeutics, 2017
- MicroRNAs and lipid metabolismCurrent Opinion in Lipidology, 2017
- Modulation of microRNA Expression in Subjects with Metabolic Syndrome and Decrease of Cholesterol Efflux from Macrophages via microRNA-33-Mediated Attenuation of ATP-Binding Cassette Transporter A1 Expression by StatinsPLOS ONE, 2016
- Atorvastatin for lowering lipidsCochrane Database of Systematic Reviews, 2015
- MicroRNA-590 attenuates lipid accumulation and pro-inflammatory cytokine secretion by targeting lipoprotein lipase gene in human THP-1 macrophagesBiochimie, 2014
- miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalingProceedings of the National Academy of Sciences, 2011
- MicroRNAs in lipid metabolismCurrent Opinion in Lipidology, 2011
- Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and CanadaEuropean Journal of Preventive Cardiology, 2011